Esophageal Diseases  >>  capecitabine  >>  Phase 2
Welcome,         Profile    Billing    Logout  

7 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
capecitabine / Generic mfg.
NCT00583674 / 2007-003573-50: Phase 2 Study of AMG 386 (20060439) in Combination With Cisplatin & Capecitabine in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma

Completed
2
171
US, Europe, RoW
AMG 386 placebo, AMG 386 10mg/kg, AMG 386 3mg/kg, Cisplatin, Capecitabine
Amgen
Gastrointestinal Cancer
03/10
06/12
XAGastric, NCT00447330: Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma

Checkmark capecitabine, oxaliplatin, and bevacizumab in met esophagogastric adenocarcinomas
Mar 2013 - Mar 2013: capecitabine, oxaliplatin, and bevacizumab in met esophagogastric adenocarcinomas
Completed
2
60
US
capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin)
Duke University, Hoffmann-La Roche, Sanofi, Genentech, Inc.
Esophageal Neoplasms, Stomach Neoplasms, Neoplasm Metastasis
01/14
07/14
NCT00737438: Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma

Checkmark ASCO-GI 2013
Jan 2013 - Jan 2013: ASCO-GI 2013
Completed
2
22
US
epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan, Patients who have a poor PET response to cycle 1 of ECX plus bevacizumab, (eg. < 35% FDG reduction on the week 3 PET scan compared with baseline), will be switched to salvage therapy of docetaxel and irinotecan (DI)., This treatment will be administered on week 1 and 2 of a 3, week cycle for 2 cycles. Patients will receive bevacizumab for the 1st cycle, of salvage docetaxel/irinotecan only. There is again a planned 10-12 week time, interval (eg. 70-84 days) between the last bevacizumab treatment and surgery.
Memorial Sloan Kettering Cancer Center, Genentech, Inc., Weill Medical College of Cornell University
Esophageal Cancer, Gastric Cancer
02/15
02/15
NCT00719550 / 2008-001605-42: AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer

Checkmark As 1st line treatment for gastric/oesophagogastric junction adenocarcinoma
Jun 2014 - Jun 2014: As 1st line treatment for gastric/oesophagogastric junction adenocarcinoma
Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Checkmark
More
Completed
1b/2
130
US, Canada, Europe, RoW
Capecitabine, Xeloda, Epirubicin, AMG 102, Cisplatin, Placebo
Amgen
Esophagogastric Junction Adenocarcinoma, Gastric Cancer, Esophageal Cancer
11/10
06/13
POXX, NCT00578071: Phase I/II Study of Panitumumab, Capecitabine and Oxaliplatin w EBRT for Esophageal Cancer

Completed
1/2
29
US
Panitumumab, Capecitabine, Xeloda, Oxaliplatin, Radiation Therapy (RT)
Brian Czito, Amgen
Cancer of the Esophagus
07/11
06/12
ACTION, NCT02273713: The Addition of Nab-paclitaxel (Abraxane) to First Line Treatment of Metastasized Oesophagogastric Carcinoma

Completed
1/2
154
Europe
Nab-paclitaxel, Abraxane
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Celgene Corporation
Esophageal Cancer, Toxicity
03/17
03/17
NCT01490749: Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer

Completed
1/2
17
US
RAD001, Everolimus, XELOX, Oxaliplatin and capecitabine, Eloxatin and Xeloda, Carboplatin, Paraplatin, Radiation
Emory University, Novartis
Esophageal Cancer, Neoplasms, Esophageal
02/19
02/19

Download Options